FDA's Woodcock says change needed in US

9 April 2014 - Deborah Wilkes

Archived

The Food and Drug Administration (FDA) made its position on the US OTC drug review clear at the start of the recent public hearing on the future of the 40 year-old regulatory system. "The system has served us well, but we don’t see it serving us well going forward unless we make some changes," said Dr Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER).

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: